ReviewNeurology2024
Does Surgical Removal of the Thymus Have Deleterious Consequences?
Review in Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Can Non-Thymomatous Late-Onset Myasthenia Gravis Benefit From Thymectomy? A Systematic Review and Meta-Analysis.European journal of neurology · 2025Pooled it
- Thymic epithelial tumors: what's next?Cancer metastasis reviews · 2026Review
- Myasthenia Gravis and Thymoma.Muscle & nerve · 2026Review
- Long-Term Cancer and Mortality After Thymectomy.European journal of neurology · 2026Article
- The Effect of Thymectomy on the Incidence of Extrathymic Cancers and Autoimmune Diseases in Patients With Non-Thymomatous Myasthenia Gravis.Muscle & nerve · 2026Article
- Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody-Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation.CNS neuroscience & therapeutics · 2026Article
- An inflammation-nutrition-surgery-based INSEP model and a web-based clinical decision support system for predicting early postoperative infection in elderly patients with hepatocellular carcinoma: a multicenter retrospective study.Frontiers in nutrition · 2026Article
- Measuring thymic output across the human lifespan: a critical challenge in laboratory medicine.GeroScience · 2025Review
- Mesenchymal stromal cells conditioned by peripheral blood mononuclear cells exert enhanced immunomodulation capacities and alleviate a model of Myasthenia Gravis.Stem cell research & therapy · 2025Article
- Aging and immunity: the age-old tango.Genes & development · 2025Review
- Article
- Preoperative multiclass classification of thymic mass lesions based on radiomics and machine learning.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Thymic hyperplasia in myasthenia gravis: a narrative review.Mediastinum (Hong Kong, China) · 2025Review
- Survival and autoimmune risks post-thymectomy.Frontiers in immunology · 2025Article
- Myasthenia gravis: the future is here.The Journal of clinical investigation · 2024Review
- Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study.Therapeutic advances in neurological disorders · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of immunosenescence, particularly the natural process of thymic involution during aging, is increasingly acknowledged as a factor contributing to the development of autoimmune diseases and cancer. Recently, a concern has been raised about deleterious consequences of the surgical removal of thymic tissue, including for patients who undergo thymectomy for myasthenia gravis (MG) or resection of a thymoma. This review adopts a multidisciplinary approach to scrutinize the evidence concerning the long-term risks of cancer and autoimmunity postthymectomy. We conclude that for patients with acetylcholine receptor antibody-positive MG and those diagnosed with thymoma, the removal of the thymus offers prominent benefits that well outweigh the potential risks. However, incidental removal of thymic tissue during other thoracic surgeries should be minimized whenever feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.